Skip to content
About Us
Services & Solutions
News & Resources
Catalog Product
Careers
Contact Us
Start a project

Oligonucleotide platform

Oligonucleotide

WuXi TIDES oligonucleotide platform provides comprehensive CRDMO services from drug discovery to commercial manufacturing for both drug substance and drug product.

End to End CRDMO Platform for Drugs

WuXi TIDES oligonucleotide platform provides comprehensive CRDMO services from drug discovery to commercial manufacturing for both drug substance and drug product.

Our oligonucleotide discovery synthesis services support high throughput library synthesis and custom synthesis (nmol-mmol). We cover all types of oligonucleotides, their monomers, linkers, ligands and conjugates. Additionally, we provide dedicated analytical support for all required testing.

We can seamlessly scale up to any scale (mmol – mol) to meet various demands from preclinical, clinical to commercial stages with ample capacities and proven capabilities with commercial success. Beyond chemistry, we provide formulation development and manufacturing services with various dosage forms and filling formats. These services are coupled with comprehensive analytical support for both API and drug product under one quality system, as well as the integrated CMC dossier preparation services, enabling our customers to bring their oligonucleotide therapeutics to market faster.

Oligonucleotide CRDMO Chemistry Platform

from Discovery to Development and Commercial Manufacturing

Monomer / Ligand
Oligonucleotide (from nmol to mol)
  • DNA | ASO | PMO
  • miRNA | siRNA | sgRNA
  • Aptamer
  • Degenerate Oligonucleotide Pools
Conjugate

Services and Solutions

Discovery Synthesis

Oligonucleotide

Conjugate

Monomer & Ligand

Development & Manufacturing

API

Drug Product

Analytical

Regulatory CMC

Why WuXi TIDES

What this platform adds

01

Scalability

From discovery to commercialisation entirely within WuXi TIDES, with readily available large R&D and manufacturing capacity.

02

Conjugation Chemistry

Seamless collaboration across the oligonucleotide, peptide and small molecule teams — the conjugates nobody else wants to touch.

03

New Technology

Biocatalysis for gRNA synthesis, thin film evaporation, reactor-in-series with PAT, continuous flow chromatography, TFF.

04

Global Quality Standard

One quality system across every site, approved by the major regulatory agencies around the world.

05

Comprehensive Analytical

Method development and validation, IPC and release testing, characterisation and stability under one roof.

06

Integrated CMC

API and formulation development, manufacturing, analytical, dossier preparation and clinical supply as a single programme.

Meeting global quality standards

Inspection record

0
US FDA
2013–2025
0
EU EMA
2009–2025
0
China NMPA
2015–2025
0
Japan PMDA
2019–2024
0
South Korea MFDS
2022
0
SwissMedic
2018–2025

How can we help?

Our TIDES drug experts stand ready.

Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.

Small molecule projects? WuXi STA